Plasma levels of catecholamines and asymmetric dimethylarginine levels as predictive values of mortality among hemodialysis patients

1. Agarwal R. et al.: Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am. J. Med., 115, 291, 2003.Search in Google Scholar

2. Aldamiz-Echevarria L., Andrade F.: Asymmetric dimethylarginine, endothelial dysfunction and renal disease. Int. J. Mol. Sci.,13, 11288, 2012.Search in Google Scholar

3. Alsagaff M.Y. et al.: Asymmetric dimethylarginine: a novel cardiovascular risk factor in end-stage renal disease. J. Int. Med. Res., 40, 340, 2012.10.1177/14732300120400013522429374Search in Google Scholar

4. Arici M., Walls J.: End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int., 59, 407, 2001.Search in Google Scholar

5. Bassareo P.P. et al.: Urinary NGAL and hematic ADMA levels: an early sign of cardio-renal syndrome in young adults born preterm? J. Matern. Fetal Neonatal Med., 26, 80, 2013.10.3109/14767058.2013.82969824059560Search in Google Scholar

6. Bassareo P.P. et al.: Could ADMA levels in young adults born preterm predict an early endothelial dysfunction? Int. J. Cardiol., 159, 217, 2012.10.1016/j.ijcard.2011.02.06921420186Search in Google Scholar

7. De Jager D.J. et al.: Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA, 302, 1782, 2009.10.1001/jama.2009.148819861670Search in Google Scholar

8. Goonasekera C.D. et al.: Nitric oxide synthase inhibitors and hypertension in children and adolescents. J. Hypertens., 15, 901, 1997.10.1097/00004872-199715080-000159280214Search in Google Scholar

9. Guerin A, Pannier B, London G.: Atherosclerosis versus arterial stiffness in advanced renal failure. Adv. Cardiol.,44, 187, 2007.Search in Google Scholar

10. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis., 39, 1, 2002.Search in Google Scholar

11. Kielstein J.T. et al.: Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J. Am. Soc.Nephrol., 13, 170, 2002.10.1681/ASN.V13117011752034Search in Google Scholar

12. Kielstein J.T. et al.: Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J. Am. Soc. Nephrol., 10, 594, 1999.10.1681/ASN.V10359410073610Search in Google Scholar

13. Kielstein J.T. et al.: Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press. Res., 27, 143, 2004.10.1159/00007883815192321Search in Google Scholar

14. Koch M. et al.: Relevance of conventional cardiovascular risk factors for the prediction of coronary artery disease in diabetic patients on renal replacement therapy. Nephrol. Dial. Transplant., 12, 1187, 1997.10.1093/ndt/12.6.11879198049Search in Google Scholar

15. Luyckx V.A., Brenner B.M. Low birth weight, nephron number and kidney disease. Kidney Int., 97, 68, 2005.Search in Google Scholar

16. Mallamaci F. et al.: Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J. Am. Soc. Nephrol., 15, 435, 2004.10.1097/01.ASN.0000106717.58091.F6Search in Google Scholar

17. Nakayama Y. et al.: Asymmetric dimethylarginine accumulates in the kidney during ischemia/reperfusion injury. Kidney Int., 9, 1, 2013.Search in Google Scholar

18. Perticone F. et al.: Endothelial dysfunction, ADMA and insulin resistance in essential hypertension. Int. J. Cardiol., 142, 236, 2010.Search in Google Scholar

19. Raptis V., Kapoulas S., Grekas D.: Role of asymmetrical dimethylarginine in the progression of renal disease. Nephrology (Carlton), 18, 11, 2013.Search in Google Scholar

20. Rocha M.S. et al.: Asymmetric dimethylarginine in adults with cystathionine β-synthase deficiency. Atherosclerosis, 222, 509, 2012.10.1016/j.atherosclerosis.2012.03.00922484094Search in Google Scholar

21. Rodriguez M.M. et al.: Comparative renal histomorphometry: a case study of oligonephropathy of prematurity. Pediatr. Nephrol., 20, 945, 2005.10.1007/s00467-004-1800-x15856326Search in Google Scholar

22. Rutkowski B. et al.: Raport o stanie leczenia nerkozastępczego w Polsce 2009. Drukonsul, Gdańsk 2010.Search in Google Scholar

23. Sarnak M.J., Levey A.S.: Epidemiology, diagnosis, and management of cardiac disease in chronic renal disease. J. Thromb. Thrombolysis, 10, 169, 2000.Search in Google Scholar

24. Schwarz P. et al.: Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves. Circ. Res., 77, 841, 1995.10.1161/01.RES.77.4.8417554131Search in Google Scholar

25. Sesti G. et al.: A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with chronic kidney disease.Atherosclerosis, 231, 141, 2013.10.1016/j.atherosclerosis.2013.08.04124125425Search in Google Scholar

26. Sibal L. et al.: The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr. Cardiol.Rev., 6, 82, 2010.10.2174/157340310791162659289208021532773Search in Google Scholar

27. Sydow K. et al.: Distribution of asymmetric dimethylarginine among 980 healthy, older adults of different ethnicities. Clin. Chem., 56, 111, 2010.10.1373/clinchem.2009.13620019892843Search in Google Scholar

28. Tripepi G. et al.: Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients.Clin. J. Am. Soc. Nephrol., 6, 1714, 2011.10.2215/CJN.1129121021642364Search in Google Scholar

29. U.S. Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2013.Search in Google Scholar

30. Ueda S. et al.: Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease. Nephrology, 12, 582, 2007.10.1111/j.1440-1797.2007.00840.x17995585Search in Google Scholar

31. Wilcken D.E. et al.: Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of l-arginine on its metabolism. Mol. Genet. Metab., 91, 309, 2007.10.1016/j.ymgme.2007.04.01717560156Search in Google Scholar

32. Zoccali C. et al.: Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J. Am.Soc. Nephrol., 13, 490, 2002.Search in Google Scholar

33. Zoccali C. et al:. Inflammation is associated with carotid atherosclerosis in dialysis patients. J. Hypertens., 18, 1207, 2000.10.1097/00004872-200018090-0000610994751Search in Google Scholar